Xeris Pharmaceuticals Inc. (XERS) Misses Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events
March 10, 2022 7:00 AM ESTAcquisition and integration of Strongbridge Biopharma completed; $50M in synergies to be realized by year-end 2022
Recorlev® approved by FDA
FY 21 pro forma net product revenues of $79M a 56% increase from prior year
Well-capitalized with cash, cash equivalents, and short-term investments of $102.4M at YE 2021
Double-digit net product revenues growth expected in 2022 to be $105M - $120M
Cash position further strengthened with a recent PIPE and the restructuring of debt with Hayfin Capital; 2022 year-end cash, cash equivalents,... More
